23,945 results on '"Guillain-Barre syndrome"'
Search Results
2. Ventilator Trigger Sensitivity Adjustment Versus Threshold Inspiratory Muscle Training on Arterial Blood Gases
- Author
-
El-Sayed Essam, Lecturer at Department of Physical Therapy for Cardiovascular/Respiratory Disorder and Geriatrics, Faculty of Physical Therapy, Cairo University
- Published
- 2024
3. Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome
- Author
-
argenx and Chafic Karam, Staff Physician and Associate Professor of Clinical Neurology
- Published
- 2024
4. Artificial Intelligence-powered Virtual Assistant for Emergency Triage in Neurology (AIDEN)
- Author
-
Entelai and Mauricio F. Farez, PI
- Published
- 2024
5. Prognostic Indicators of Gullian-Barre Syndrome
- Author
-
Amira Abdelhakem Sayed Amin, Pricipal Investigator
- Published
- 2024
6. A Study of Imlifidase in Patients With Guillain-Barré Syndrome
- Published
- 2024
7. A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome
- Published
- 2024
8. Predictive Value of Neuromuscular Ultrasound of Cranial Nerves in Guillain-Barré Syndrome
- Author
-
mohamed abdallah abdalraziq ahmed, resident doctor
- Published
- 2024
9. Differential diagnosis of Guillain-Barré syndrome: steroid-responsive radiculopathy in Evans syndrome.
- Author
-
Schulten, Thomas, Meyer, Ansgar, Krug, Utz, and Lehmann, Helmar C.
- Abstract
Guillain-Barré syndrome is the most common acute inflammatory demyelinating peripheral nerve condition. Occasionally, other autoimmune conditions can mimic Guillain-Barré syndrome but may require different diagnostic workup and treatment. We report here two patients with Evans syndrome, a rare hematological autoimmune condition who developed a subacute inflammatory radiculopathy. Similarities and distinguishing clinical and diagnostic features are discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Exploring causal correlations between plasma proteins and peripheral neuropathy: a Mendelian randomization.
- Author
-
Man Song, Fang Chen, Xiaocong Li, and Lu Chen
- Subjects
BLOOD proteins ,CARPAL tunnel syndrome ,GENOME-wide association studies ,GUILLAIN-Barre syndrome ,DIABETIC neuropathies - Abstract
Background: Peripheral neuropathy (PN) is a common neurological disorder, and circulating plasma proteins with causal genetic evidence are a major source of therapeutic targets. This study identifies several potential plasma proteins that are causally related to PN risk, providing new insights into protein-mediated pathogenesis of PN and potential targets for novel therapies. Methods: To identify potential therapeutic targets for PN, we employed twosample Mendelian randomization (MR) to identify plasma proteins associated with six common PN. First, we screened for proteins related to PN using genomewide association studies (GWAS), obtaining genetic data on plasma proteomes from 35,559 Icelanders. Summary data for six common PN, including Carpal Tunnel Syndrome (CTS), Trigeminal Neuralgia (TN), Alcoholic Neuropathy (AIP), Drug-induced Neuropathy (DIP), Diabetic Neuropathy (DP), and Guillain-Barré syndrome (GBS), were obtained from the FinnGen database. Two-sample MR and colocalization analyses were then conducted to further identify proteinPN pairs with presumed causal relationships. Enrichment analysis of positive proteins revealed potential biological processes and pathways. Based on druggene interaction analysis, we ultimately identified causal proteins associated with PN that could serve as potential drug targets for treating PN. Results: Through MR analysis, we identified eight proteins (UBC12, SEM4C, IL23R, Prothrombin, CBS, Microglobulin, MATN4, COLEC12) with causal relationships to PN. We found that UBC12 is a protective factor for DP and CTS, while the remaining proteins are risk factors. Further colocalization analysis showed a posterior probability of hypothesis 4 (PPH4) less than 0.75, indicating no positive colocalization results were found. From the pathway enrichment analysis, we discovered that the proteins were mainly concentrated in pathways related to defense response to bacterium, receptor signaling pathway via STAT, cell killing, negative regulation of cytokine production, and leukocyte mediated immunity. Finally, in Drug-Gene Interaction database (DGIdb), we identified three protein-coding genes (IL23R, F2, CBS) as potential drug targets for PN. Conclusion: Mendelian randomization studies confirm the causal relationship between genetically predicted PN-related risk and genetically predicted plasma protein abundance. Plasma proteins, as biomarkers associated with PN, can provide potential drug targets for etiological intervention research in PN. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Temporal trends and regional variations in mortality related to Guillain-Barré syndrome in the United States: a retrospective study from 1999 to 2020.
- Author
-
Nadeem, Zain Ali, Ashraf, Hamza, Ashfaq, Haider, Fatima, Eeshal, Larik, Muhammad Omar, Ur Rehman, Obaid, Ashraf, Ali, and Nadeem, Aimen
- Subjects
- *
RACE , *ALASKA Natives , *GUILLAIN-Barre syndrome , *PACIFIC Islanders , *DEATH rate - Abstract
AbstractAimMethodsResultsConclusionsGuillain-Barré syndrome (GBS) is an autoimmune neurological disorder, with an estimated 6.4% increase in cases worldwide from 1990 to 2019. We aim to identify the GBS-related mortality trends in the US stratified by age, sex, race, and region.We used data from the CDC-WONDER database to calculate crude (CMR) and age-adjusted mortality rates (AAMRs) per 1,000,000 people. We examined the temporal trends through annual percent change (APC) and the average annual percent change (AAPC) in rates using Joinpoint regression.From 1999 to 2020, a total of 10,097 GBS-related deaths occurred in the US. The AAMR decreased till 2014 (APC: −1.91) but increased back to initial levels by 2020 (APC: 3.77). AAMR was higher in males (1.7) than females (1.1), decreasing till 2015 for females and 2014 for males, but increasing thereafter only for females. Non-Hispanic (NH) American Indians or Alaska Natives displayed the highest AAMR (1.8) while NH Asians or Pacific Islanders displayed the lowest (0.6). AAMRs also varied by region (West: 1.5; South: 1.5; Midwest: 1.4; Northeast: 1.1). Rural regions exhibited a higher AAMR (1.7) than urban regions (1.3). Most deaths occurred in medical facilities (60.99%). The adults aged ≥85 years exhibited an alarmingly high CMR (14.0).While the mortality rates for GBS initially declined till 2014, they climbed back up afterwards. Highest mortality was exhibited by males and NH American Indians or Alaska Natives, residents of rural regions, and adults ≥85 years. Equitable efforts are needed to reduce the burden on high-risk populations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Guillain-Barré Syndrome: An Ayurvedic Approach To Understanding And Treating It: A Single Case Study.
- Author
-
Dubey, Kshitij Kumar, Deva, Sachin, and B., Divya
- Subjects
GUILLAIN-Barre syndrome ,NEURONS ,COVID-19 ,MUSCLE weakness ,INTRAVENOUS injections ,POLYNEUROPATHIES - Abstract
Acute inflammatory demyelinating polyneuropathy Guillain-Barre's syndrome is typically brought on by an immunological reaction following certain post-infections. GBS causes nerve damage resulting in muscle weakness, tingling sensation and paralysis due to nerve injury. (1) It can be comparable to Sarvangavata, according to Ayurveda. The fatty myelin coating that surrounds the nerve cells protects them. The neurological system requires an insulating layer to operate properly, which is created as a result. It can also be compared to medogata vata. Since myelin contains about 40% water, the dry mass is made up of 60% to 75% lipid and 15% to 25% protein. (2) Ayurveda offers Panchakarma therapy to lessen the sickness by easing the symptoms of GBS. A 55-year-old male patient was unable to sit, stand or walk due to abrupt onset of weakness in both lower limbs. The patient was also covid 19 positive, one month before the onset of these symptoms. For the same patient has been hospitalised and underwent proper covid management. Eventually complaints of weakness in the lower limbs and GBS led the patient to seek additional medical attention and receive IV Ig injections. After receiving immunoglobulin therapy there was no expected recovery. Hence the patient has been admitted to our hospital as in patient for further management. [ABSTRACT FROM AUTHOR]
- Published
- 2024
13. Efficacy and safety of eculizumab in Guillain‐Barré syndrome: A phase 3, multicenter, double‐blind, randomized, placebo‐controlled clinical trial.
- Author
-
Kuwabara, Satoshi, Kusunoki, Susumu, Kuwahara, Motoi, Yamano, Yoshihisa, Nishida, Yoichiro, Ishida, Hirokazu, Kasuya, Tomoyuki, Kupperman, Erik, Lin, Qun, Frick, Glen, and Misawa, Sonoko
- Subjects
- *
INTRAVENOUS immunoglobulins , *PLACEBOS , *IMMUNOSUPPRESSIVE agents , *MEDICAL quality control , *PATIENT safety , *RESEARCH funding , *STATISTICAL sampling , *BLIND experiment , *GUILLAIN-Barre syndrome , *TREATMENT effectiveness , *RANDOMIZED controlled trials , *DESCRIPTIVE statistics , *MONOCLONAL antibodies , *INTRAVENOUS therapy , *ODDS ratio , *RESEARCH , *CONVALESCENCE , *COMPARATIVE studies , *CONFIDENCE intervals , *PLASMA exchange (Therapeutics) , *PHARMACODYNAMICS - Abstract
Background and Aims: Guillain‐Barré syndrome (GBS) is an acute, self‐limited, immune‐mediated peripheral neuropathy. Current treatments for GBS include intravenous immunoglobulin (IVIg) and plasma exchange, which may not sufficiently benefit severely affected patients. This study evaluated the efficacy and safety of eculizumab add‐on therapy to IVIg (standard‐of‐care treatment) in patients with severe GBS. Methods: This phase 3, multicenter, double‐blind, randomized, placebo‐controlled clinical trial (NCT04752566), enrolled Japanese adults (age ≥ 18 years) with severe GBS (Hughes functional grade [FG] score FG3 or FG4/FG5 within 2 weeks of onset of GBS). Participants were randomized 2:1 to receive intravenous infusion of eculizumab or placebo (once weekly for 4 weeks) with IVIg treatment with 20 weeks of follow‐up. Primary efficacy endpoint was the time to first reach FG score ≤1 (able to run). Key secondary endpoints were proportion of participants achieving FG ≤1 at weeks 8 and 24 and FG improvement ≥3 at week 24. Pharmacodynamic analysis of serum free C5 concentration over time was performed. Safety was evaluated. Results: The analysis included 57 participants (eculizumab, n = 37; placebo, n = 20). Primary endpoint was not achieved (hazard ratio, 0.9; 95% CI, 0.45–1.97; p =.89). Key secondary endpoints did not reach statistical significance. Serum C5 concentration was reduced by 99.99% at 1 h postdose and sustained to week 5 but returned to baseline at the end of follow‐up period. No new safety signals for eculizumab were identified. Interpretation: Although well tolerated, eculizumab treatment did not show significant effects on motor function recovery compared to placebo in patients with GBS. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Electrodiagnostic subtyping in Guillain–Barré syndrome patients in the International Guillain–Barré Outcome Study.
- Author
-
Arends, Samuel, Drenthen, Judith, de Koning, Laura, van den Bergh, Peter, Hadden, Robert D. M., Kuwabara, Satoshi, Reisin, Ricardo C., Shahrizaila, Nortina, Ajroud‐Driss, Senda, Antonini, Giovanni, Attarian, Shahram, Balducci, Claudia, Bertorini, Tulio, Brannagan, Thomas H., Cavaletti, Guido, Chao, Chi‐Chao, Chavada, Govind, Dillmann, Klaus‐Ulrich, Dimachkie, Mazen M., and Galassi, Giuliana
- Abstract
Background and purpose: Various electrodiagnostic criteria have been developed in Guillain–Barré syndrome (GBS). Their performance in a broad representation of GBS patients has not been evaluated. Motor conduction data from the International GBS Outcome Study (IGOS) cohort were used to compare two widely used criterion sets and relate these to diagnostic amyotrophic lateral sclerosis criteria. Methods: From the first 1500 patients in IGOS, nerve conduction studies from 1137 (75.8%) were available for the current study. These patients were classified according to nerve conduction studies criteria proposed by Hadden and Rajabally. Results: Of the 1137 studies, 68.3% (N = 777) were classified identically according to criteria by Hadden and Rajabally: 111 (9.8%) axonal, 366 (32.2%) demyelinating, 195 (17.2%) equivocal, 35 (3.1%) inexcitable and 70 (6.2%) normal. Thus, 360 studies (31.7%) were classified differently. The areas of differences were as follows: 155 studies (13.6%) classified as demyelinating by Hadden and axonal by Rajabally; 122 studies (10.7%) classified as demyelinating by Hadden and equivocal by Rajabally; and 75 studies (6.6%) classified as equivocal by Hadden and axonal by Rajabally. Due to more strictly defined cutoffs fewer patients fulfilled demyelinating criteria by Rajabally than by Hadden, making more patients eligible for axonal or equivocal classification by Rajabally. In 234 (68.6%) axonal studies by Rajabally the revised El Escorial (amyotrophic lateral sclerosis) criteria were fulfilled; in axonal cases by Hadden this was 1.8%. Conclusions and discussion: This study shows that electrodiagnosis in GBS is dependent on the criterion set utilized, both of which are based on expert opinion. Reappraisal of electrodiagnostic subtyping in GBS is warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Role of prazosin in patients with Guillain–Barré syndrome with sympathetic overactivity: A cohort study.
- Author
-
Kumar, Mritunjai, Guin, Abhishek, Singh, Anu, Singh, Rajni, and Tiwari, Ashutosh
- Subjects
- *
DIASTOLIC blood pressure , *PRAZOSIN , *MEDICAL registries , *DYSAUTONOMIA , *HYPERKINESIA - Abstract
Introduction/Aims Methods Results Discussion In Guillain–Barré syndrome (GBS), patients with dysautonomia demonstrate sympathetic overactivity (SO). This study assessed the role of prazosin (α1‐blocker) in the management of SO.This cohort study was conducted from January 2022 to September 2023. Thirty‐two GBS patients with SO received prazosin (2.5–10 mg three times a day) (prazosin group). For comparison, we included historical controls that included 33 GBS patients having SO with similar baseline characteristics, including median age and disability, who did not receive prazosin, from a GBS registry of patients admitted during February 2018–December 2021. The primary endpoint was days to resolution of SO. Secondary endpoints were daily fluctuations in the systolic (SBP) and diastolic blood pressure (DBP), duration of hospital stay, in‐hospital mortality, and disability at 3 months.The median ages of both the treatment and the control groups were 36 (IQR 25–49) years and 43 (66.2%) were males. The demographic and clinical parameters were comparable. Prazosin resulted in significantly earlier normalization of SO compared to the control group (median 15 vs. 20 days; p = .01). The mean fluctuations in the SBP and DBP at 15 days were significantly lower in the prazosin group. However, the duration of hospital stay and good recovery at 3 months were comparable. Three patients developed hypotension, while two patients died (ventilator‐associated pneumonia) in the prazosin group.This study provides new evidence supporting the role of prazosin in SO, and needs randomized trials to confirm our findings. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Maternal and newborn outcomes in pregnancies complicated by Guillain-Barré syndrome.
- Author
-
Taylor, Samantha, Czuzoj-Shulman, Nicholas, Spence, Andrea R., and Abenhaim, Haim A.
- Subjects
- *
PREGNANCY outcomes , *PERIPHERAL nervous system , *GUILLAIN-Barre syndrome , *PREGNANT women , *PUERPERIUM - Abstract
Guillain-Barré syndrome (GBS) is a rare autoimmune disorder that affects the peripheral nervous system. The purpose of our study was to evaluate maternal and fetal/neonatal outcomes among pregnancies complicated by GBS.We performed a retrospective cohort study using the Healthcare Cost and Utilization Project – National Inpatient Sample from the United States. ICD-9 codes were used to identify all pregnant women who delivered between 1999 and 2015 and had a diagnosis of GBS. The remaining women without GBS who delivered during that time period constituted the comparison group. The associations between maternal GBS and obstetrical and fetal/neonatal outcomes were evaluated using multivariate logistic regression, while adjusting for the confounding effects of maternal characteristics.Of 13,792,544 births included in our study, 291 were to women with GBS, for an overall incidence of 2.1/100,000 births. A steady increase in maternal GBS was observed over the study period (from 1.26 to 3.8/100,000 births, p
= 0.02). Further, women with GBS were more likely to have pregnancies complicated by preeclampsia, OR 1.69 (95 % CI 1.06–2.69), sepsis, 9.30 (2.33–37.17), postpartum hemorrhage, 1.83 (1.07–3.14), and to require a transfusion, 4.39 (2.39–8.05). They were also at greater risk of caesarean delivery, 2.07 (1.58–2.72) and increased length of hospital stay, 4.48 (3.00–6.69). Newborns of women with GBS were more likely to be growth restricted, 2.50 (1.48–4.23).GBS in pregnancy is associated with maternal and newborn adverse outcomes. These patients would benefit from close follow-up throughout their pregnancy and in the postpartum period. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
17. Exploring the adverse events of Oxford–AstraZeneca, Pfizer-BioNTech, Moderna, and Johnson and Johnson COVID-19 vaccination on Guillain–Barré Syndrome.
- Author
-
Meo, Sultan Ayoub, Shaikh, Narmeen, Abukhalaf, Farah Adnan, and Meo, Anusha Sultan
- Subjects
- *
SARS-CoV-2 , *COVID-19 vaccines , *GUILLAIN-Barre syndrome , *VACCINATION complications - Abstract
The vaccination against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is an important public health strategy to prevent people from the pandemic. Vaccines are a game-changing tool, it is essential to understand the adverse events after COVID-19 vaccination. This study explored the adverse events of COVID-19 Vaccination Oxford–AstraZeneca, Pfizer-BioNTech, Moderna, Johnson and Johnson on Guillain–Barré Syndrome (GBS). In this study, initially 128 documents were identified from the databases, including Pub-Med, Web of Science-Clarivate Analytics, Scopus, and Google Scholar. The articles on COVID-19 vaccination and GBs were searched using the keywords "SARS-CoV-2, COVID-19, Vaccination, and Guillain Barré Syndrome, GBS", finally, 16 documents were included in the analysis and synthesis. After administering 1,680,042,214 doses of COVID-19 vaccines, 6177 cases were identified with 10.5 cases per million vaccine doses. A significant positive risk was found between COVID-19 vaccine administration and GBS with a risk rate of RR 1.97 (95% CI 1.26–3.08, p = 0.01). The mRNA vaccines were associated with 2076 cases, and 1,237,638,401 vaccine doses were linked with 4.47 GBS events per million vaccine doses. The first dose of the m-RNA vaccine was associated with 8.83 events per million doses compared to the second dose with 02 events per million doses. The viral-vector vaccine doses 193,535,249 were linked to 1630 GBS cases with 11.01 cases per million doses. The incidence of GBS after the first dose was 17.43 compared to 1.47 cases per million in the second dose of the viral-vector vaccine. The adverse events of the Oxford–AstraZeneca vaccine were linked to 1339 cases of GBS following 167,786,902 vaccine doses, with 14.2 cases per million doses. The Oxford–AstraZeneca vaccine significantly increased the risk of GBS RR: 2.96 (95% CI 2.51–3.48, p = 0.01). For the Pfizer-BioNTech vaccine, there were 7.20 cases per million doses of the vaccine, and no significant association was identified between the Pfizer-BioNTech vaccine and GBS incidence RR: 0.99 (95% CI 0.75–1.32, p = 0.96). Moderna vaccine was related with 419 cases of GBS after administering 420,420,909 doses, with 2.26 cases per million doses. However, Johnson and Johnson's vaccination was linked to 235 GBS after 60,256,913 doses of the vaccine with 8.80 cases per million doses. A significant association was seen between the risk of GBS and Ad.26.COV2. S vaccine, RR: 2.47 (95% CI 1.30–4.69, p < 0.01). Overall, a significant association was seen between the COVID-19 vaccines and the risk of GBS. The incidence of GBS was higher after the first dose compared to GBS cases per million in the second dose. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Tracing the origin of NDM-1-producing and extensively drug-resistant Pseudomonas aeruginosa ST357 in the Netherlands.
- Author
-
Rossel, Connor A. J., Hendrickx, Antoni P. A., van Alphen, Lieke B., van der Horst, Robrecht P. J., Janssen, Augustinus H. J. W., Kooyman, Cornelia C., and Heddema, Edou R.
- Subjects
- *
WHOLE genome sequencing , *PSEUDOMONAS aeruginosa , *GUILLAIN-Barre syndrome , *DRUG resistance in microorganisms , *CRITICALLY ill , *KLEBSIELLA pneumoniae , *KLEBSIELLA infections - Abstract
Background: In the hospital environment, carbapenemase-producing Pseudomonas aeruginosa (CPPA) may lead to fatal patient infections. However, the transmission routes of CPPA often remain unknown. Therefore, this case study aimed to trace the origin of CPPA ST357, which caused a hospital-acquired pneumonia in a repatriated critically ill patient suffering from Guillain-Barré Syndrome in 2023. Methods: Antimicrobial susceptibility of the CPPA isolate for 30 single and combination therapies was determined by disk-diffusion, Etest or broth microdilution. Whole-genome sequencing was performed for three case CPPA isolates (one patient and two sinks) and four distinct CPPA ST357 patient isolates received in the Dutch CPPA surveillance program. Furthermore, 193 international P. aeruginosa ST357 assemblies were collected via three genome repositories and analyzed using whole-genome multi-locus sequence typing in combination with antimicrobial resistance gene (ARG) characterization. Results: A Dutch patient who carried NDM-1-producing CPPA was transferred from Kenya to the Netherlands, with subsequent dissemination of CPPA isolates to the local sinks within a month after admission. The CPPA case isolates presented an extensively drug-resistant phenotype, with susceptibility only for colistin and cefiderocol-fosfomycin. Phylogenetic analysis showed considerable variation in allelic distances (mean = 150, max = 527 alleles) among the ST357 isolates from Asia (n = 92), Europe (n = 58), Africa (n = 21), America (n = 16), Oceania (n = 2) and unregistered regions (n = 4). However, the case isolates (n = 3) and additional Dutch patient surveillance program isolates (n = 2) were located in a sub-clade of isolates from Kenya (n = 17; varying 15–49 alleles), the United States (n = 7; 21–115 alleles) and other countries (n = 6; 14–121 alleles). This was consistent with previous hospitalization in Kenya of 2/3 Dutch patients. Additionally, over half of the isolates (20/35) in this sub-clade presented an identical resistome with 9/17 Kenyan, 5/5 Dutch, 4/7 United States and 2/6 other countries, which were characterized by the blaNDM-1, aph(3')-VI, ARR-3 and cmlA1 ARGs. Conclusion: This study presents an extensively-drug resistant subclone of NDM-producing P. aeruginosa ST357 with a unique resistome which was introduced to the Netherlands via repatriation of critically ill patients from Kenya. Therefore, the monitoring of repatriated patients for CPPA in conjunction with vigilance for the risk of environmental contamination is advisable to detect and prevent further dissemination. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. A nationwide Guillain–Barré syndrome epidemiological study in Spain during the COVID‐19 years.
- Author
-
Blanco‐Ruiz, Marina, Martín‐Aguilar, Lorena, Caballero‐Ávila, Marta, Lleixà, Cinta, Pascual‐Goñi, Elba, Collet‐Vidiella, Roger, Tejada‐Illa, Clara, Turon‐Sans, Janina, Carbayo, Álvaro, Llansó, Laura, Cortés, Elena, Amaya Pascasio, Laura, and Querol, Luis
- Subjects
- *
SARS-CoV-2 , *COVID-19 , *OLDER people , *HOSPITAL admission & discharge , *SEASONAL variations of diseases - Abstract
Background and purpose Methods Results Conclusions The purpose was to perform a nationwide epidemiological study of Guillain–Barré syndrome (GBS) in Spain, analysing background incidences and seasonal variation and trying to identify incidence changes during the coronavirus disease 2019 (COVID‐19) years.This was an observational study collecting all GBS diagnoses from the National Epidemiological Surveillance Network collected by the Ministry of Health. Patients discharged with GBS as the main diagnosis and admitted during 2018–2021 were included. Data on the incidence of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infections were obtained from the National Epidemiology Centre.In total, 3147 cases were included, 832 in 2018, 861 in 2019, 670 in 2020 and 784 in 2021. Nationwide hospital incidence was 1.78 in 2018, 1.71 in 2019, 1.41 in 2020 and 1.66 in 2021, with an increased frequency in males, the elderly population and in the winter season. Eleven per cent of GBS patients needed ventilatory support. GBS and SARS‐CoV‐2 incidences did not correlate with one another (r = −0.29, p = 0.36). GBS incidence decreased during 2020 and during the COVID‐19 lockdown period in comparison to the same months of 2018–2019.The incidence of GBS in Spain is similar to that of other countries. Despite prior reports describing a significant increase in COVID‐19‐associated GBS in Spain, a significant drop of GBS incidence during the SARS‐CoV‐2 pandemic was detected, probably due to prevention measures. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Multiple cerebral infarctions after intravenous immunoglobulin for Guillain-Barre' syndrome: two case reports and review of the literature.
- Author
-
Weisen Wang, Chunhua Feng, Yanqun Liu, Yi Tao, Xiaoying Bi, and Xiaojun Hou
- Subjects
ACUTE flaccid paralysis ,CORONARY artery disease ,GUILLAIN-Barre syndrome ,MAGNETIC resonance imaging ,LITERATURE reviews ,CEREBRAL infarction - Abstract
Background: Guillain-Barre' syndrome (GBS) is a polyradiculoneuropathy mediated by the immune system and is the primary reason for acute flaccid paralysis. Intravenous immunoglobulin (IVIg) is a recognized immunotherapeutic drug that can accelerate recovery from GBS. Limited literature exists concerning cerebral infarction complications with IVIg following its use in the treatment of GBS. Case presentation: A patient was diagnosed with the acute inflammatory demyelinating polyradiculoneuropathy subtype of GBS, while another patient was diagnosed with the acute bulbar palsy variant of GBS 2 years prior and experienced a relapse of GBS. Both patients received immunoglobulin therapy, during which multiple acute cerebral infarctions were detected using magnetic resonance imaging. Both patients had a history of coronary artery atherosclerotic heart disease and vertebral artery stenosis, and D-dimer and fibrinogen degradation products were significantly elevated after immunoglobulin therapy. Conclusions: The risk of cerebral infarction associated with IVIg is generally low in patients with different GBS variants. Nevertheless, the occurrence of cerebral infarction associated with IVIg might not be insignificant in older patients with vascular risk factors and should be carefully monitored. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Clinical Characteristics and Prognosis of ICU-Admitted Patients with Guillain-Barre Syndrome: A Report from a Large Teaching Hospital in South Iran.
- Author
-
Naderi-boldaji, Vida, Zand, Farid, Asmarian, Naeimehossadat, Marbooti, Hoda, Masjedi, Mansoor, Tabibzadeh, Seyedeh Maryam, Esmaeilinezhad, Zahra, and Nazeri, Masoume
- Subjects
- *
TREATMENT of Guillain-Barre syndrome , *PNEUMONIA , *URINARY tract infections , *ACADEMIC medical centers , *RESEARCH funding , *HOSPITAL care , *SYMPTOMS , *TREATMENT effectiveness , *RETROSPECTIVE studies , *DESCRIPTIVE statistics , *GUILLAIN-Barre syndrome , *INTENSIVE care units , *MEDICAL records , *ACQUISITION of data , *ARTIFICIAL respiration , *SEPSIS , *DATA analysis software , *APACHE (Disease classification system) - Abstract
Background: Guillain-Barre Syndrome (GBS) is the most prevalent acute peripheral polyneuropathy disorder. The disparities between populations and variations in the major risk factors highlight the importance of country-specific studies. This study aimed to report clinical characteristics and outcomes of ICU-admitted patients with GBS in an academic medical center in Iran. Methods: The data were collected retrospectively from all patients with GBS admitted to Namazi Hospital, affiliated with Shiraz University of Medical Sciences, (Shiraz, Iran), between March 2016 to March 2021. Specialized neurological information and the Acute Physiology and Chronic Health Evaluation (APACHE II) score were recorded. The SPSS software was used to analyze the data. The analyzed data were reported as numbers and percentages, or mean±SD, or median(Interquartile) Results: The study included 132 GBS patients, with an average age of 47.87±15.4 years and a male-to-female ratio of 1.69:1. More than half of the patients (58.5%) were classified as having an axonal disease. In patients with axonal illness, 51.4% of patients had lower limb powers<3, while only 36% of those had the demyelinating disease. This group also required mechanical ventilation more frequently (54% vs. 46%) and for a longer duration (26 [9-37] vs. 10 [1-61]) days. Pneumonia and sepsis were each observed in 16% of patients, and 12% developed a urinary tract infection. The most common type of GBS was acute inflammatory demyelinating polyneuropathy (AIDP). Only 6 (3.8%) patients died. Conclusion: The axonal type of GBS was more frequent, and these patients required mechanical ventilation more frequently and for a longer duration than those in other electrophysiological categories. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Advances in Exosome-Based Therapies for the Repair of Peripheral Nerve Injuries.
- Author
-
Rahimian, Sana, Najafi, Hossein, Webber, Christine A., and Jalali, Hanieh
- Subjects
- *
PERIPHERAL nerve injuries , *DIABETIC neuropathies , *NEUROLOGICAL disorders , *PERIPHERAL nervous system , *GUILLAIN-Barre syndrome , *EXTRACELLULAR vesicles - Abstract
Peripheral nerve injuries (PNIs) are the term used to describe injuries that occur to the nerve fibers of the peripheral nervous system (PNS). Such injuries may be caused by trauma, infection, or aberrant immunological response. Although the peripheral nervous system has a limited capacity for self-repair, in cases of severe damage, this process is either interrupted entirely or is only partially completed. The evaluation of variables that promote the repair of peripheral nerves has consistently been a focal point. Exosomes are a subtype of extracellular vesicles that originate from cellular sources and possess abundant proteins, lipids, and nucleic acids, play a critical role in facilitating intercellular communication. Due to their modifiable composition, they possess exceptional capabilities as carriers for therapeutic compounds, including but not limited to mRNAs or microRNAs. Exosome-based therapies have gained significant attention in the treatment of several nervous system diseases due to their advantageous properties, such as low toxicity, high stability, and limited immune system activation. The objective of this review article is to provide an overview of exosome-based treatments that have been developed in recent years for a range of PNIs, including nerve trauma, diabetic neuropathy, amyotrophic lateral sclerosis (ALS), glaucoma, and Guillain-Barre syndrome (GBS). It was concluded that exosomes could provide favorable results in the improvement of peripheral PNIs by facilitating the transfer of regenerative factors. The development of bioengineered exosome therapy for PNIs should be given more attention to enhance the efficacy of exosome treatment for PNIs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Vaccine patterns among older adults with Guillain–Barré syndrome and matched comparators, 2006–2019.
- Author
-
Eiffert, Samantha R., Kinlaw, Alan C., Sleath, Betsy L., Thorpe, Carolyn T., Traub, Rebecca, Raman, Sudha R., and Stürmer, Til
- Subjects
- *
TETANUS vaccines , *OLDER people , *AUTOIMMUNE diseases , *COMPARATOR circuits , *VACCINATION - Abstract
Background Methods Results Conclusions Some vaccines have a small risk of triggering Guillain–Barré syndrome (GBS), an autoimmune disorder where nerve damage leads to paralysis. There is a CDC precaution for patients whose GBS was associated with an influenza or tetanus toxoid‐containing vaccine (GBS occurring within 42 days following vaccination).We described vaccine patterns before and after a GBS diagnosis with a matched cohort design in a 20% random sample of fee‐for‐service Medicare enrollees. We defined the index date as an ICD‐9‐CM or ICD‐10‐CM GBS diagnosis code in the primary position of an inpatient claim. We matched each GBS patient to five non‐GBS comparators on sex, exact age, racial and ethnic category, state of residence and the month of preventive health visits during baseline; used weighting to balance covariates; and measured frequency of vaccines received per 100 people during year before and after the index date using the weighted mean cumulative count (wMCC).We identified 1567 patients with a GBS diagnosis with at least 1 year of prior continuous enrollment in Medicare A and B that matched to five comparators each. The wMCCs in the 1 year before the index date were similar for both groups, with a wMCC of 74 vaccines/100 people in the GBS group (95% CI 71, 77). Within 1 year after the index date, patients with GBS had received 26 vaccines/100 people (95% CI 23, 28), which was 41 fewer vaccines than matched non‐GBS comparators (95% CI −44, −38). Among GBS patients, 11% were diagnosed with GBS within 42 days after a vaccine.GBS diagnosis has a strong impact on reducing subsequent vaccination even though there is no warning or precaution about future vaccines for most patients diagnosed with GBS. These data suggest discordance between clinical practice and current vaccine recommendations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Guillain‐Barré syndrome: a comprehensive review.
- Author
-
Bellanti, Roberto and Rinaldi, Simon
- Subjects
- *
GUILLAIN-Barre syndrome , *THERAPEUTICS , *NERVOUS system injuries , *ARTIFICIAL respiration , *MEDICAL personnel , *MUCOCUTANEOUS lymph node syndrome - Abstract
Guillain‐Barré syndrome (GBS) is a potentially devastating yet treatable disorder. A classically postinfectious, immune‐mediated, monophasic polyradiculoneuropathy, it is the leading global cause of acquired neuromuscular paralysis. In most cases, the immunopathological process driving nerve injury is ill‐defined. Diagnosis of GBS relies on clinical features, supported by laboratory findings and electrophysiology. Although previously divided into primary demyelinating or axonal variants, this dichotomy is increasingly challenged, and is not endorsed by the recent European Academy of Neurology (EAN)/Peripheral Nerve Society (PNS) guidelines. Intravenous immunoglobulin and plasma exchange remain the primary modalities of treatment, regardless of the electrophysiological subtype. Most patients recover, but approximately one‐third require mechanical ventilation, and 5% die. Disease activity and treatment response are currently monitored through interval neurological examination and outcome measures, and the potential role of fluid biomarkers is under ongoing scrutiny. Novel potential therapies for GBS are being explored but none have yet modified clinical practice. This review provides a comprehensive update on the pathological and clinical aspects of GBS for clinicians and scientists. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Anti-neurofascin-155 antibody mediated a distinct phenotype of chronic inflammatory demyelinating polyradiculoneuropathy.
- Author
-
Zhang, Lijie, Zhang, Yuanyuan, Li, Runyun, Zhu, Jiting, Lin, Aiyu, Yan, Yaping, Zhang, Zaiqiang, Wang, Ning, Xu, Guorong, and Fu, Ying
- Subjects
- *
CHRONIC inflammatory demyelinating polyradiculoneuropathy , *T helper cells , *B cells , *GUILLAIN-Barre syndrome , *IMMUNE response , *POLYNEUROPATHIES - Abstract
Background: To investigate Ranvier's autoantibodies prevalence and isotypes in various peripheral neuropathy variants, compare clinical features between seronegative and seropositive patients, and elucidate immune mechanisms underlying antibody generation. Methods: Antibodies against anti-neurofascin-155 (NF155), NF186, contactin-1 (CNTN1), CNTN2, contactin-associated protein 1 (CASPR1), and CASPR2 were identified through cell-based assays. Plasma cytokines were analyzed in anti-NF155 antibody-positive chronic inflammatory demyelinating polyneuropathy (NF155+ CIDP) and Ranvier's antibodies-negative CIDP (Ab− CIDP) patients using a multiplexed fluorescent immunoassay, validated in vitro in a cell culture model. Results: In 368 plasma samples, 50 Ranvier's autoantibodies were found in 45 individuals, primarily in CIDP cases (25 out of 69 patients) and in 10 out of 122 Guillain-Barré syndrome patients. Anti-NF155 and CNTN1-IgG were exclusive to CIDP. Fourteen samples were NF155-IgG, primarily IgG4 subclass, linked to CIDP features including early onset, tremor, sensory disturbance, elevated CSF protein, prolonged motor latency, conduction block, and poor treatment response. NF155-IgG had low sensitivity (20.28%) but high specificity (100%) for CIDP, rising to 88.88% with tremor and prolonged motor latency. Cytokine profiling in NF155+ CIDP revealed distinct immune responses involving helper T cells, toll-like receptor pathways. Some NF155+ CIDP patients had circulating NF155-specific B cells producing NF155-IgG without antigen presence, suggesting therapeutic potential. Conclusion: The study emphasizes the high specificity and sensitivity of NF155-IgG for diagnosing CIDP characterized by distinctive features. Further investigation into circulating NF155-specific B cell phenotypes may pave the way for B cell directed therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Clinical, paraclinical and outcome features of 166 patients with acute anti-GQ1b antibody syndrome.
- Author
-
Coly, Martin, Adams, David, Attarian, Shahram, Bouhour, Françoise, Camdessanché, Jean-Philippe, Carey, Guillaume, Cauquil, Cécile, Chanson, Jean-Baptiste, Chrétien, Pascale, Créange, Alain, Delmont, Emilien, Fargeot, Guillaume, Frachet, Simon, Gendre, Thierry, Kuntzer, Thierry, Labeyrie, Céline, Maisonobe, Thierry, Michaud, Maud, Moulin, Maximilien, and Nicolas, Guillaume
- Subjects
- *
NERVE conduction studies , *SENSORY ataxia , *CEREBROSPINAL fluid , *CAMPYLOBACTER infections , *INTRAVENOUS immunoglobulins , *PARANEOPLASTIC syndromes - Abstract
Background & purpose: In this retrospective study, we aimed at defining the clinical, paraclinical and outcome features of acute neurological syndromes associated with anti-GQ1b antibodies. Results: We identified 166 patients with neurological symptoms appearing in less than 1 month and anti-GQ1b antibodies in serum between 2012 and 2022. Half were female (51%), mean age was 50 years (4–90), and the most frequent clinical features were areflexia (80% of patients), distal upper and lower limbs sensory symptoms (78%), ophthalmoplegia (68%), sensory ataxia (67%), limb muscle weakness (45%) and bulbar weakness (45%). Fifty-three patients (32%) presented with complete (21%) and incomplete (11%) Miller Fisher syndrome (MFS), thirty-six (22%) with Guillain–Barre syndrome (GBS), one (0.6%) with Bickerstaff encephalitis (BE), and seventy-three (44%) with mixed MFS, GBS & BE clinical features. Nerve conduction studies were normal in 46% of cases, showed demyelination in 28%, and axonal loss in 23%. Anti-GT1a antibodies were found in 56% of cases, increased cerebrospinal fluid protein content in 24%, and Campylobacter jejuni infection in 7%. Most patients (83%) were treated with intravenous immunoglobulins, and neurological recovery was complete in 69% of cases at 1 year follow-up. One patient died, and 15% of patients relapsed. Age > 70 years, initial Intensive Care Unit (ICU) admission, and absent anti-GQ1b IgG antibodies were predictors of incomplete recovery at 12 months. No predictors of relapse were identified. Conclusion: This study from Western Europe shows acute anti-GQ1b antibody syndrome presents with a large clinical phenotype, a good outcome in 2/3 of cases, and frequent relapses. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Guillain-Barre syndrome after snakebite: a case report and systematic review.
- Author
-
Çakırgöz, Mensure Yımaz, Aksun, Murat, Üstün, Damlanur, Yılmaz, Özgün, and Akan, Mert
- Subjects
- *
MOTOR neuron diseases , *GUILLAIN-Barre syndrome , *SEPTIC shock , *MEDICAL literature , *CEREBROSPINAL fluid , *SNAKEBITES - Abstract
Guillain-Barré Syndrome (GBS) is a polyneuropathy characterized by acute-onset and immune-mediated processes, triggered by various factors. The occurence of GBS in connection with snakebites is rare. In this report, we present a rare clinical case with neuro-muscular and hematological complications following a snakebite, leading to flask quadriplegia on the 14th day during intensive care follow-up. Cerebrospinal fluid (CSF) analysis indicated albumin-cytological dissociation, and Electromyography (EMG) revealed findings consistent with acute motor axonal neuropathy, resulting in a diagnosis of GBS. After undergoing plasmapheresis once, the patient swiftly developed refractory septic shock, leading to a fatal outcome. In this study, we report a GBS case as a conseqeunce of snakebite together with a systematic review of the medical literature on the development of GBS after snakebite. Although current case reports and findings have broadened the scope of etiologic hypotheses for GBS including snake envenomation, further studies are needed to confirm the association between GBS following snakebite. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. SÍNDROME DE GUILLAIN-BARRÉ.
- Author
-
de Faria Chaimowicz, Beatriz, Vieira de Menezes, Bruno Petrocchi, Duarte Coutinho, Camila Hostalacio, Barbosa Santos, Clara Chagas, and Ribeiro Sternick, Letícia
- Subjects
GUILLAIN-Barre syndrome ,PERIPHERAL nervous system ,NEUROLOGICAL disorders ,SYMPTOMS ,LITERATURE reviews - Abstract
Copyright of Revista Foco (Interdisciplinary Studies Journal) is the property of Revista Foco and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
- Full Text
- View/download PDF
29. Additional Rehabilitative Robot-Assisted Gait Training for Ambulation in Geriatric Individuals with Guillain–Barré Syndrome: A Case Report.
- Author
-
Chen, Fred Yi-Shueh, Hou, Wen-Hsuan, Lee, Hsun-Hua, Huang, Ying-Chi, and Siow, Co Yih
- Subjects
ACTIVITIES of daily living ,OLDER patients ,PATIENT experience ,FATIGUE (Physiology) ,MUSCLE strength ,BED rest - Abstract
We present a case of a 75-year-old Asian woman with Guillain–Barré syndrome (GBS) who underwent a 1-month comprehensive rehabilitation training program supplemented by robot-assisted gait training (RAGT). GBS can lead to fatigue and prolonged bed rest, thereby further debilitating older patients. Although exercise intervention is recommended for GBS, a consensus regarding the appropriate intensity has yet to be established. Individualized strategies are required because older patients experience varying levels of fatigue and frailty. We used a technological adjunct to support comprehensive rehabilitation for GBS reconditioning in an older patient. To the best of our knowledge, research involving the use of an exoskeleton robotic device in the geriatric population with GBS is limited. Our case demonstrates the feasibility and safety of RAGT for improving lower limb muscle power and scores on the Barthel Index, Clinical Frailty Scale, and Instrumental Activities of Daily Living Scale at discharge from a geriatric ward. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. A rare presentation of acute-onset chronic inflammatory demyelinating polyneuropathy with the detection of anti-GM3 and anti-sulfatides antibodies: a case report.
- Author
-
Ruohan Sun, Yao Meng, Lingyu Li, Wei-hong Chen, Jing Xu, Peiyuan Lv, and Yanhong Dong
- Subjects
CHRONIC inflammatory demyelinating polyradiculoneuropathy ,INTRAVENOUS immunoglobulins ,GUILLAIN-Barre syndrome ,DEMYELINATION ,PERIPHERAL nervous system ,POLYNEUROPATHIES - Abstract
Objectives: Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired immune-mediated neuropathy defined by clinical progression for more than 2 months. 16-20% of CIDP patients may present with rapidly progressive weakness that resembles GBS, known as acute-onset CIDP (A-CIDP). However, it is challenging to distinguish from GBS-TRF because of their similar clinical symptom and features. In this case review, we report a patient with A-CIDP with the detection of anti-GM3 and anti-sulfatides antibodies, which rarely have been in A-CIDP and may account for her progressive and recurrent symptoms. Methods: We analyzed existing medical literature and described a clinical case of A-CIDP with antibodies positive. Results: We reported a 56-year-old female presented with bilateral lower extremity weakness and distal numbness. She experienced similar symptoms four times and responded well to the IVIg therapy. Lumbar puncture demonstrated albumin-cytologic dissociation and EDX examination revealed multiple peripheral nerve damage. After ruling out other demyelination diseases, a diagnosis of A-CIDP was made. Discussion: The antiganglioside and anti-sulfatide antibodies are involved in CIDP pathogenesis and can help to distinguish A-CIDP and other variants. To prevent secondary damage, it is important to monitor relapse and remission symptoms along the treatment line. A rare case of A-CIDP is discussed concerning the detection of anti-GM3 and anti-sulfatides antibodies, thus making a retrospective comparison of antibodies in some literature to understand A-CIDP better. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Risk factors and outcome of hyponatremia in patients with Guillain–Barré syndrome.
- Author
-
Ogawa, Shoji, Hosokawa, Takafumi, Hayakawa, Chizuko, Sawai, Taiki, Kakiuchi, Kensuke, Nishioka, Daisuke, Yoshimoto, Yukiyo, Masuda, Yuichi, Nakamura, Yoshitsugu, Ota, Shin, and Arawaka, Shigeki
- Subjects
- *
GUILLAIN-Barre syndrome , *MECHANICAL ventilators , *SEPSIS , *RETENTION of urine , *DYSAUTONOMIA , *HYPONATREMIA - Abstract
The objective of the present study was to evaluate the risk factors and outcomes associated with hyponatremia in patients with Guillain-Barré syndrome (GBS). We retrospectively studied 80 consecutive patients with GBS who visited our hospital and compared clinical, laboratory, and electrophysiological findings of patients with and without hyponatremia. Disability was evaluated using the Hughes grading system. Of the 80 patients, 18 (23%) had hyponatremia. Hyponatremia was significantly associated with older age (P = 0.003), urinary retention (P < 0.0001), Hughes grade ≥ 4 at admission and nadir (P = 0.003 and P < 0.001, respectively), acute inflammatory demyelinating polyneuropathy subtype (P = 0.017), sepsis (P = 0.001), mechanical ventilator support (P = 0.013), longer hospitalization length of stay (P < 0.0001), and inability to walk independently at 6 months (P < 0.001). Multivariate analysis performed to assess the risk factors of hyponatremia revealed that urinary retention (odds ratio [OR] 30.7, 95% confidence interval [CI] 3.6–264.4; P = 0.002) and mechanical ventilator support (OR 13.8, 95% CI 1.6–118.0; P = 0.017) were significant independent risk factors of hyponatremia. In assessing the outcomes of patients with hyponatremia, multivariate analysis showed that hyponatremia was independently associated with hospitalization length of stay ≥ 60 days and inability to walk independently at 6 month, with the former showing statistical significance but the latter not (OR 9.3, 95% CI 1.8–47.7; P = 0.007 and OR 4.9, 95% CI 0.9–26.3; P = 0.066, respectively). Therefore, we demonstrate that, along with mechanical ventilator support, urinary retention—possibly indicating autonomic dysfunction—is a risk factor of hyponatremia in GBS. Moreover, we confirm that hyponatremia is associated with poor outcome in GBS. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. Guillain-Barré Syndrome and Encephalitis Following a Cytomegalovirus Infection in an Immunocompetent Adult: A Case Report.
- Author
-
Araujo Coelho, David Richer, Melo Mendes, Isabel Cristina, Flores Mamani, Roxana, Oliveira da Luz, Rogerio, Martins de Oliveira, Ana Luiza, and Pimentel, Clarisse
- Subjects
- *
PATHOLOGY , *GUILLAIN-Barre syndrome , *CYTOMEGALOVIRUS diseases , *SEIZURES (Medicine) , *SYMPTOMS - Abstract
Objective: Rare coexistence of disease or pathology Background: Cytomegalovirus (CMV) is a common herpesvirus that often causes asymptomatic or mild infections. In immunocompromised patients, CMV can lead to severe complications, including Guillain-Barré syndrome (GBS) and encephalitis. While these conditions have been described in the immunocompetent population, simultaneous presentation of CMV-associated GBS and encephalitis in such individuals has not been previously reported. Case Report: We present a case of a 58-year-old woman with poorly controlled diabetes who developed concurrent GBS and encephalitis following a CMV infection. The patient experienced bilateral ascending paraparesis 1 week after self-limited gastrointestinal symptoms. Despite initial treatment with plasma exchange therapy, her condition deteriorated with altered mental status and generalized tonic-clonic seizures, necessitating orotracheal intubation. Laboratory analysis revealed the presence of CMV in her cerebrospinal fluid. After treatment with further sessions of plasma exchange therapy and ganciclovir, her muscular strength in the extremities improved. However, she developed acute lung edema and failed extubation, leading to cardiorespiratory arrest with neurological sequelae. Palliative care was institutionalized, and she died 2 weeks later due to pneumonia. Conclusions: This case highlights an unusual clinical presentation of overlapping CMV-associated GBS and encephalitis in an immunocompetent individual, with diabetes as the only identified risk factor. It underscores the importance of considering CMV as a potential etiological factor in such complex cases and the need for prompt diagnosis to improve patient outcomes. Further research is warranted to explore the underlying mechanisms and implications of this rare overlapping neurological manifestation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. Genetic association between gut microbiota and the risk of Guillain-Barré syndrome.
- Author
-
Cao, Fangzheng, Zhang, Houwen, Xu, Bin, and Li, Chunrong
- Subjects
- *
GUILLAIN-Barre syndrome , *GUT microbiome , *GENOME-wide association studies , *AUTOIMMUNE diseases - Abstract
Guillain-Barré Syndrome (GBS) is an autoimmune disease that typically develops after a previous gastrointestinal (GI) infection. However, the exact association between Gut Microbiota (GM) and GBS still remains unknown due to various challenges. This study aimed to investigate the potential causal association between GM and GBS by using a two-sample Mendelian Randomization (TSMR) analysis. Utilizing the largest available genome-wide association study (GWAS) meta-analysis from the MiBioGen consortium (n = 13,266) as a foundation, we conducted a TSMR to decipher the causal relationship between GM and GBS. Various analytical methods were employed, including the inverse variance weighted (IVW), MR-PRESSO, MR-Egger, and weighted median. The heterogeneity of instrumental variables (IVs) was assessed using Cochran's Q statistics. The analysis identified three microbial taxa with a significantly increased risk association for GBS, including Ruminococcus gnavus group (OR = 1.40, 95 % CI: 1.07–1.83), Ruminococcus gauvreauii group (OR = 1.51, 95 % CI: 1.02–2.25), and Ruminococcaceae UCG009 (OR = 1.42, 95 % CI: 1.02–1.97), while Eubacterium brachy group (OR = 1.44, 95 % CI: 1.10–1.87) and Romboutsia (OR = 1.67, 95 % CI: 1.12–2.47) showed a suggestively causal association. On the other hand, Ruminococcaceae UCG004 (OR = 0.61, 95 % CI: 0.41–0.91) had a protective effect on GBS, while Bacilli (OR = 0.60, 95 % CI: 0.38–0.96), Gamma proteobacteria (OR = 0.63, 95 % CI: 0.41–0.98) and Lachnospiraceae UCG001 (OR = 0.69, 95 % CI: 0.49–0.96) showed a suggestively protective association for GBS. The MR analysis suggests a potential causal relationship between specific GM taxa and the risk of GBS. However, further extensive research involving diversified populations is imperative to validate these findings. • The association between Gut Microbiota (GM) and Guillain-Barré Syndrome (GBS) remains unknown due to various challenges; • This is the first study to identify the causal effects of GM on GBS through Two-sample Mendelian randomization analysis; • Our results may provide new evidence for potential causal relationship between specific GM taxa and the risk of GBS. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. Recent advances in the study of zika virus structure, drug targets, and inhibitors.
- Author
-
Yingqi Feng
- Subjects
DRUG target ,CYTOSKELETAL proteins ,DRUG design ,GUILLAIN-Barre syndrome ,RNA viruses ,ZIKA virus - Abstract
Zika Virus (ZIKV) is a positive-strand RNA virus that can lead to Guillain-Barré syndrome or encephalitis in some individuals and hence presents a serious public health risk. Since the first outbreak of ZIKV in Brazil in 2015, no effective clinical inhibitors have been developed, making the development of effective ZIKV drugs an urgent issue that needs to be addressed. ZIKV belongs to the Flaviviridae family, and its structure includes three structural proteins, namely, capsular (C), premembrane (prM), and envelope (E) proteins, as well as seven nonstructural proteins, namely, NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5. To provide a reference for the development of future ZIKV drugs, this paper reviews the structure of the ZIKV based on recent literature reports, analyzes the potential therapeutic targets of various proteins, and proposes feasible drug design strategies. Additionally, this paper reviews and classifies the latest research progress on several protease inhibitors, such as E protein inhibitors, NS2BNS3 inhibitors, and NS5 inhibitors, so that researchers can quickly understand the current status of development and the interconnections among these inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. Case report and brief literature review: possible association of secukinumab with Guillain-Barre' syndrome in psoriasis.
- Author
-
Gang Liang, Yongmei Han, Haiyan He, Ci Lu, and Chen Zhu
- Subjects
LITERATURE reviews ,GUILLAIN-Barre syndrome ,DRUG side effects ,CONSCIOUSNESS raising ,IMMUNE checkpoint inhibitors - Abstract
The etiology of Guillain-Barre' syndrome (GBS) may be autoimmune. About twothirds of patients typically experience their first symptoms within 5 days to 3 weeks after common infectious diseases, surgery, or vaccination. Infection is a triggering factor for over 50% of patients. In recent years, a growing number of studies have indicated that some immune checkpoint inhibitors and COVID-19 may also contribute to the occurrence of GBS. However, drugs are considered a rare cause of GBS. The patient in our case was a 70-year-old man who developed GBS after initiating secukinumab for psoriasis. Upon diagnosis suggesting a potential association between secukinumab and the development of GBS, as per the Naranjo adverse drug reaction (ADR) probability scale, we decided to discontinue the drug. Following this intervention, along with the administration of immunoglobulin, the patient exhibited a significant improvement in extremity weakness. The association of GBS with secukinumab treatment, as observed in this case, appears to be uncommon. The underlying mechanisms that may link secukinumab to the development of GBS are not yet fully understood and warrant further scientific inquiry and rigorous investigation. However, we hope that this report can raise greater awareness and vigilance among medical professionals to enhance the safety of patients' medication. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. Memory inflation: Beyond the acute phase of viral infection.
- Author
-
Li, Yanfei, Xiao, Jie, Li, Chen, and Yang, Mu
- Subjects
- *
T cells , *VIRUS diseases , *MEMORY , *IMMUNOLOGIC memory , *GUILLAIN-Barre syndrome - Abstract
Memory inflation is confirmed as the most commonly dysregulation of host immunity with antigen‐independent manner in mammals after viral infection. By generating large numbers of effector/memory and terminal differentiated effector memory CD8+ T cells with diminished naïve subsets, memory inflation is believed to play critical roles in connecting the viral infection and the onset of multiple diseases. Here, we reviewed the current understanding of memory inflated CD8+ T cells in their distinct phenotypic features that different from exhausted subsets; the intrinsic and extrinsic roles in regulating the formation of memory inflation; and the key proteins in maintaining the expansion and proliferation of inflationary populations. More importantly, based on the evidences from both clinic and animal models, we summarized the potential mechanisms of memory inflation to trigger autoimmune neuropathies, such as Guillain‐Barré syndrome and multiple sclerosis; the correlations of memory inflation between tumorigenesis and resistance of tumour immunotherapies; as well as the effects of memory inflation to facilitate vascular disease progression. To sum up, better understanding of memory inflation could provide us an opportunity to beyond the acute phase of viral infection, and shed a light on the long‐term influences of CD8+ T cell heterogeneity in dampen host immune homeostasis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. A retrospective analysis of the clinical profile and factors associated with mortality and poor hospital outcomes in adult Guillain–Barre syndrome patients.
- Author
-
Tewedaj, Zinabu Derso, Huluka, Dawit Kebede, Kebede, Yabets Tesfaye, Abebe, Abel Tezera, Hussen, Meksud Shemsu, Mohammed, Bekri Delil, and Juhar, Leja Hamza
- Subjects
- *
GUILLAIN-Barre syndrome , *HOSPITAL mortality , *RESPIRATORY infections , *RESOURCE-limited settings , *LOGISTIC regression analysis , *NOROVIRUS diseases - Abstract
Guillain–Barré syndrome (GBS) is an acute autoimmune polyneuropathy with substantial geographic variations in demography, antecedent events, clinical manifestations, electrophysiological sub-types, diagnostic findings, treatment modalities, and prognostic indicators. However, there is limited contemporary data on GBS patient profiles and prognostic factors from low-resource settings like Ethiopia. The objective of this study is to investigate the clinical profile, factors associated with mortality, and hospital outcomes among GBS patients admitted to Tikur Anbessa Specialized Hospital (TASH) in Addis Ababa, Ethiopia. A retrospective cross-sectional study was conducted among 60 GBS patients admitted to TASH from January 2018 to December 2022. Data on demographics, clinical features, treatments, complications, and outcomes were extracted from medical records. Bivariate and multivariate logistic regression analyses identified factors associated with mortality and poor hospital outcomes. The cohort had a mean age of 28.5 years, with 76.7% aged 14–34 years. Males comprised 61.7% of cases. Ascending paralysis (76.7%) was the predominant presentation. Absent or reduced reflexes were seen in 91.7% of patients. The most common antecedent event was gastroenteritis (26.7%), followed by upper respiratory tract infection (URTI) (15%) and vaccination (11.7%). The mean interval from symptom onset to hospital presentation was 8.77 days, and the peak symptom severity was 4.47 days. The axonal variant (75.5%) was the most common subtype, followed by the demyelinating variant (24.5%). Intravenous immunoglobulin was administered to 41.7% of patients. Respiratory failure requiring invasive mechanical ventilator (MV) support occurred in 26.7% of cases. The mortality rate was 10%, with mechanical ventilation being the only factor significantly associated with mortality (95% CI 2.067–184.858; P < 0.010). At discharge, 55% had a good outcome, and 45% had a poor outcome, according to the Hughes Functional Disability Scale (HFDS). Mechanical ventilation (AOR 0.024, 95% CI 0.001–0.607) and a GBS disability score > 3 (AOR 0.106, 95% CI 0.024–0.467) were factors significantly associated with poor hospital outcomes. GBS in this cohort primarily affected individuals of young age, commonly preceded by gastroenteritis and characterized by a high frequency of the axonal variant. Mechanical ventilation was found to be significantly linked to mortality. Alongside mechanical ventilation requirements, severe disability upon presentation emerged as a crucial determinant of poor outcomes upon discharge, underscoring the importance of early identification of high-risk patients and prompt interventions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Spontaneous Resolution of Kyphoscoliosis Secondary to Guillain-Barre Syndrome: A Case Report.
- Author
-
Malka, Matan S., Givens, Ritt R., Zervos, Thomas M., Berube, Emma, Lu, Kevin, Bainton, Nikki, Vitale, Michael G., and Roye, Benjamin D.
- Subjects
- *
SPINE abnormalities , *GUILLAIN-Barre syndrome , *SEROTHERAPY , *INTRAVENOUS therapy , *CONSERVATIVE treatment - Abstract
Case: Spinal deformity associated with Guillain-Barre syndrome (GBS) is not commonly reported. We present a 6-year-old girl who developed kyphoscoliosis after being diagnosed GBS. She had extensive motor deficits requiring 2 hospitalizations and treatment with IV immunoglobulin therapy. Five months after diagnosis, she presented to our clinic with a 15° coronal scoliosis and a 65° thoracic kyphosis. At 6-month follow-up, kyphosis progressed to 77° with no significant change in the coronal curve. At 1 year, sagittal alignment was within normal limits and the coronal curve had completely resolved. Conclusion: Spinal deformity in GBS can resolve spontaneously. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. VENTILACIÓN MECÁNICA, TIEMPO DE HOSPITALIZACIÓN, MUERTES Y DISCAPACIDAD SEGÚN LAS VARIANTES DEL SÍNDROME DE GUILLAIN-BARRÉ: REVISIÓN SISTEMÁTICA Y METAANÁLISIS.
- Author
-
Castro Diaz, Silvana Ximena, Pereira-Salto, Luiza, and Araujo Castillo, Roger Vladimir
- Abstract
Objectives. To determine the requirement and time to mechanical ventilation and Intensive Care Unit (ICU), hospitalization and hospitalization time, death and disability of the axonal variants of Guillain-Barré Syndrome (GBS) in comparison with the acute demyelinating variant in patients of all the ages. Materials and methods. The systematic review that included patients with GBS. The exposure variable was the axonal variants and the comparator was acute inflammatory demyelinating polyneuropathy (AIDP). The outcomes were the requirement and time on mechanical ventilation (MV), requirement and time in the ICU, hospitalization time, disability and death. The NewCasttle-Ottawa Scale (NOS) was used to assess risk of bias. A meta-analysis was conducted to calculate mean differences and relative risks (RR) with their 95% confidence intervals (CI) using inverse variances and random effects models. Results. Of the 3116 articles found, 46 met the selection criteria. The time on MV was 7.42 days (95% CI: 0.36 to 1.48) and the hospitalization time was 3.11 (95% CI: 0.73 to 5.49) days for the axonal variants. The axonal variants had a RR of 0.47 (95% CI: 0.24 to 0.92) for the requirement of MV in adults, but it was 1.68 (95% CI: 1.25 to 2.25) in children. There was a high statistical heterogeneity. Conclusions. Axonal variants showed, on average, longer MV and hospitalization time, overall and by subgroups. A high MV requirement was found for axonal variants in children; it was lower for adults. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. Utilizing nerve conduction studies to identify very early Guillain–Barré syndrome and distinguish it from mimics in emergency settings.
- Author
-
John, Thomas and Mathew, Asha Elizabeth
- Subjects
- *
NERVE conduction studies , *GUILLAIN-Barre syndrome , *DELAYED diagnosis , *SENSITIVITY & specificity (Statistics) , *GASTROPARESIS - Abstract
Introduction/Aims Methods Results Discussion Accurately diagnosing Guillain–Barré syndrome (GBS) in its early stages and distinguishing it from mimics poses challenges. This study aimed to evaluate the utility of an existing electrodiagnostic criterion in very early GBS (VEGBS) for discerning mimics. Additionally, we explored specific electrophysiological abnormalities in VEGBS to design a new diagnostic criterion for more accurate VEGBS diagnosis.We retrospectively identified all patients with flaccid quadriparesis initially suspected of GBS who underwent nerve conduction studies (NCS) ≤4 days from symptom onset. We then retrieved their NCS data and applied an existing electrodiagnostic criterion for sensitivity and specificity analyses based on the final discharge diagnosis. Furthermore, we designed a new criterion based on the observed electrophysiological abnormalities that have maximum specificity and at least 50% sensitivity.Among 70 patients suspected of VEGBS, 44 (63%) received a final diagnosis of GBS, while in 26 (37%), the GBS diagnosis was later refuted. Umapathi's definite criterion exhibited a sensitivity of 61.36% and a specificity of 92.31%. The probable and possible groups showed very high sensitivity (90.91% and 100%, respectively); however, specificity was low (57.69% and 30.77%, respectively) in the very early stage. Our proposed criterion demonstrated a sensitivity of 88.64% (CI: 75.44%–96.21%) and a specificity of 96.15% (CI: 80.36%–99.90%).The criterion based on presumed electrophysiological correlates of specific early GBS pathophysiology proved more effective than the existing electrodiagnostic criterion in differentiating VEGBS from mimics. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Guillain-Barré Syndrome Following Lung Adenocarcinoma Surgery: A Case Report and Literature Review.
- Author
-
Sarubbi, Antonio, Frasca, Luca, Longo, Filippo, Sarubbi, Domenico, Suriano, Ilaria, Catamerò, Alberto, Sposato, Luciano Cialì, Marziali, Valentina, and Crucitti, Pierfilippo
- Subjects
- *
LUNG surgery , *LITERATURE reviews , *GUILLAIN-Barre syndrome , *NERVE conduction studies , *INTRAVENOUS immunoglobulins , *PARESTHESIA , *TEMPORAL lobectomy - Abstract
Objective: Unusual clinical course Background: Guillain-Barré syndrome (GBS) is a rare immune-mediated peripheral nerve disorder. Among non-infectious factors, surgery has been identified as a potential trigger of the disease. This report presents the case of a 74-yearold man who developed GBS 15 days after a right lower lobectomy for lung adenocarcinoma. Case Report: We present a case of a patient who was a former smoker who underwent uniportal video-assisted (U-VATS) right lower lobectomy for localized lung adenocarcinoma. Fifteen days after surgery, he exhibited bilateral lower- limb weakness, widespread paresthesia, and postural instability. Comprehensive diagnostic workup, including clinical assessment, serological tests, cerebrospinal fluid (CSF) analysis, and nerve conduction studies (NCS), confirmed the diagnosis. Notably, CSF analysis revealed albumin-cytological dissociation, with albumin 453.2 mg/L, protein 757 mg/L, glucose 67 mg/dl, 3 white blood cells (WBC)/uL, and polymorphonucleates (PMN) 33%. NCS demonstrated motor and sensory abnormalities. Prompt administration of intravenous immunoglobulins (IVIG) 2 g/kg daily for 5 days resulted in complete recovery within 3 months. Conclusions: This case emphasizes the importance of prompt recognition and management of GBS as a postoperative complication. Neurological examination, neuroimaging, and electrophysiological studies are essential for accurate diagnosis. IVIG therapy remains a cornerstone in GBS management, with favorable outcomes observed in this case. Enhanced awareness among clinicians about the potential association between surgery and GBS is vital to prevent more serious complications and ensure optimal patient management. Further research is crucial to determine the precise pathogenesis and mechanisms of GBS following lung surgery. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. PRESenting a Challenge: Posterior Reversible Encephalopathy Syndrome in Pediatric Patients With Guillain-Barré Syndrome: A Case Series and Review of Literature.
- Author
-
Surve, Rohini M., Sharma, Kunal K., Sharma, Prachi, Nisal, Roshan, Pendharkar, Hima S., and Kulkarni, Girish B.
- Subjects
- *
POSTERIOR leukoencephalopathy syndrome , *GUILLAIN-Barre syndrome , *CHILD patients , *LITERATURE reviews , *SYNDROMES in children , *ACUTE flaccid paralysis - Abstract
Guillain-Barré syndrome (GBS) is an autoimmune disorder characterized by demyelination of peripheral nerves. GBS-associated posterior reversible encephalopathy syndrome (PRES) is a rare and potentially life-threatening complication in the pediatric population. We aimed to report and analyze the clinical features, management, and outcomes of three cases of GBS-associated PRES in our setting in the light of the existing literature. Medical records of 75 pediatric patients with GBS were reviewed for autonomic changes and GBS-associated PRES. Thirty-one developed dysautonomia while three were identified to have PRES. Clinical, radiological, laboratory, and treatment data were collected and analyzed. All three patients were male and presented with symptoms of acute flaccid paralysis and respiratory distress requiring mechanical ventilation. All three patients experienced various complications, including hypertension, seizures, and hyponatremia, and were subsequently diagnosed with PRES. Multimodal intensive care resulted in patient improvement and discharge in an ambulatory state after an average of 104 days of care. GBS-associated PRES is a rare and potentially life-threatening complication that can occur in pediatric patients with GBS. Our findings suggest that early recognition, prompt intervention, and multimodal intensive care can improve patient outcomes. Further studies are needed to determine optimal treatment strategies for GBS-associated PRES. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. Antiganglioside antibody frequency in routine clinical care settings.
- Author
-
Giesche, Niklas, Böhm‐Gonzalez, Samuel Tobias, Kleiser, Benedict, Kowarik, Markus C., Dubois, Evelyn, Stransky, Elke, Armbruster, Marcel, Grimm, Alexander, and Marquetand, Justus
- Subjects
- *
CHRONIC inflammatory demyelinating polyradiculoneuropathy , *CLINICAL medicine , *MOTOR neuron diseases , *GUILLAIN-Barre syndrome , *CEREBROSPINAL fluid - Abstract
Background and purpose: Antiganglioside antibodies (AGAs) might be involved in the etiopathogenesis of many neurological diseases, such as Miller–Fisher syndrome (MFS) and Guillain–Barré syndrome (GBS). Available comprehensive reference data regarding AGA positivity rates and cross‐responsiveness among AGAs (where one line immunoblot is positive for ≥1 AGA) during routine clinical care are scant. Methods: In this 10‐year monocentric retrospective study, 3560 immunoglobulin (Ig) G and IgM line blots (GA Generic Assays' Anti‐Ganglioside Dot kit) obtained using cerebrospinal fluid (CSF) and serum samples from 1342 patients were analyzed for AGA positivity in terms of 14 diagnosis categories and AGA cross‐responsiveness. Results: Of all 3560 line blots 158 (4.4%) and of all CSF samples 0.4% (4/924) CSF line blots were AGA positive. For serum IgG, blots with positivity rates higher than the standard deviation of 15.6% were associated with MFS (GD3, GD1a, GT1a and GQ1b) and acute motor axonal neuropathy (AMAN) (GM1, GD1a and GT1a). For serum IgM, blots with positivity rates higher than the standard deviation of 8.1% were associated with AMAN (GM2, GT1a and GQ1b), MFS (GM1, GT1a and GQ1b), multifocal motor neuropathy (MMN) (GM1, GM2 and GQ1b) and chronic inflammatory demyelinating polyneuropathy (CIDP) (GM1). Cross‐responsiveness was observed in 39.6% of all positive serum AGA. Conclusions: Testing for AGAs during routine clinical care rarely led to positive findings, both in serum and even less in CSF, except for the diagnoses AMAN, MFS, MMN and CIDP. Nonspecific findings found as cross‐responsiveness between different AGA samples occur frequently, impacting the positivity of most AGA subtypes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. Takotsubo cardiomyopathy in Guillain–Barré syndrome.
- Author
-
Terayama, Atsushi, Kuwahara, Motoi, Yoshikawa, Keisuke, Yamagishi, Yuko, Samukawa, Makoto, Yamashita, Shoko, Onishi, Kyohei, Nagano, Tomoya, Tatsumi, Chikao, Ishii, Junko, Kawamoto, Michi, Tokashiki, Takashi, Deguchi, Shoko, Deguchi, Kentaro, Ishida, Atsushi, Baba, Yasuhiko, Yamaguchi, Shigeki, Kusunoki, Susumu, and Nagai, Yoshitaka
- Subjects
- *
TAKOTSUBO cardiomyopathy , *GUILLAIN-Barre syndrome , *CRANIAL nerves , *AGE of onset , *ARTIFICIAL respiration - Abstract
Background and purpose: Takotsubo cardiomyopathy (TCM) is a serious autonomic complication of Guillain–Barré syndrome (GBS). However, the association between TCM and GBS has not been investigated in detail. We investigated the characteristics of GBS patients with TCM (GBS-TCM). Methods: Clinical features and anti-ganglioside antibody between the GBS-TCM patients and 62 classical GBS patients without TCM as control patients were compared. Results: Eight GBS-TCM patients were identified, in whom TCM was diagnosed at a mean of 6.5 [range 3–42] days after the onset of GBS. The age at onset of GBS was elder in the GBS-TCM patients than in the control GBS patients (76.5 [56–87] vs. 52 [20–88] years, p < 0.01). Notably, cranial nerve deficits, particularly in the lower cranial nerves, were observed in all GBS-TCM patients (100% vs. 41.9%, p < 0.01). Additionally, the GBS-TCM patients showed a higher GBS disability score at nadir (5 [4–5] vs. 4 [1–5], p < 0.01), and lower Medical Research Council sum scores at admission and nadir (37 [30–44] vs. 48 [12–60] at admission, p < 0.05, and 20 [12–44] vs. 40 [0–60] at nadir, p < 0.05, respectively). Mechanical ventilation was more frequently required in the GBS-TCM patients (62.5% vs. 11.3%, p < 0.01). Three GBS-TCM patients were positive for anti-ganglioside antibodies. Conclusions: TCM occurred at a relatively early phase of GBS. The characteristics of GBS-TCM were the elder, lower cranial nerve involvements, severe limb weakness, and respiratory failure. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. Effect of intravenous immunoglobulin and plasmapheresis on nerve conduction parameters compared to the natural course of Guillain-Barré syndrome.
- Author
-
Kalita, Jayantee, Mahajan, Roopali, and Kumar, Mritunjai
- Abstract
• Admission NCS helped in subtyping GBS in 85% patients. • AIDP was the dominant subtype and remained so till 3 months. • 47% patients had transition in subtypes, highest from equivocal and least from AIDP. • Axonal burden was reduced and conduction block improved following IVIg. • Neurophysiological changes however were not associated with 3 months outcome. Intravenous immunoglobulin (IVIg) and plasmapheresis (PLEX) are recommended in moderate to severe Guillain-Barré Syndrome (GBS), but there is paucity of studies evaluating its effect on nerve conduction studies (NCS). We report the effect of IVIg and PLEX on the NCS parameters and clinical outcomes compared to natural course (NC) of GBS patients. Moderate to severe GBS patients were included based on clinical, cerebrospinal fluid, and NCS finding. Six motor and sensory nerves were evaluated at admission, one month and 3 months, and NCS subtyping was done. Axonal and demyelination burden in motor nerves and early reversible conduction block (ERCB) were noted. Patients receiving IVIg, PLEX or on NC were noted. Outcome was defined at 3 months into complete, partial and poor using a 0–6 GBS Disability Scale (GBSDS). Seventy-two patients were included, whose median age was 36 years and 22(30.6 %) were females. 44 patients received IVIg, 9 PLEX and 19 were in NC, and they had comparable peak disability. AIDP was the dominant subtype at admission (58.3 %), which remained so at 3 months (50 %). The shift of subtypes was the highest from the equivocal group followed by AMAN and the least from AIDP. IVIg and PLEX group had more reduction in axonal burden and had ERCB compared to NC. 33(44 %) patients had complete recovery, and 40(55.5 %) patients had concordance in clinical and neurophysiological outcome. Transition of GBS subtype may occur at follow-up from all the subtypes, the highest from the equivocal and the lowest from the AIDP group. IVIg/PLEX treatment may help in reducing conduction block and axonal burden. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. A gyermekkori Guillain-Barré-szindróma diagnosztikája és prognosztikai faktorai.
- Author
-
Dorka, Kovács, Sára, Dobner, Léna, Szabó, and Zoltán, Liptai
- Subjects
PERONEAL nerve ,CHILD patients ,GUILLAIN-Barre syndrome ,PROGNOSIS ,ELECTROPHYSIOLOGY - Abstract
Copyright of Gyermekgyógyászat is the property of Semmelweis Kiado and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
47. Interactions Between Extracellular Vesicles and Autophagy in Neuroimmune Disorders.
- Author
-
Ai, Xiwen, Yu, Haojun, Cai, Yu, and Guan, Yangtai
- Abstract
Neuroimmune disorders, such as multiple sclerosis, neuromyelitis optica spectrum disorder, myasthenia gravis, and Guillain–Barré syndrome, are characterized by the dysfunction of both the immune system and the nervous system. Increasing evidence suggests that extracellular vesicles and autophagy are closely associated with the pathogenesis of these disorders. In this review, we summarize the current understanding of the interactions between extracellular vesicles and autophagy in neuroimmune disorders and discuss their potential diagnostic and therapeutic applications. Here we highlight the need for further research to fully understand the mechanisms underlying these disorders, and to develop new diagnostic and therapeutic strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
48. Role of Balance Training in Bilateral Foot Drop Following Guillain-Barre Syndrome: Pretest-Posttest Research Design.
- Author
-
Chandra, B. Mayuri, Reddy, Nalla Kranthi, Balne, Naveen Kumar, and Gadde, Lakshmana Prasad
- Subjects
PERIPHERAL neuropathy ,PHYSICAL therapy ,MEDICAL protocols ,THERAPEUTICS ,PATIENTS ,CLINICAL trials ,GUILLAIN-Barre syndrome ,TREATMENT effectiveness ,FUNCTIONAL status ,GAIT in humans ,HOSPITALS ,PRE-tests & post-tests ,LONGITUDINAL method ,CONVALESCENCE ,QUALITY of life ,MEDICAL rehabilitation ,POSTURAL balance ,HEALTH care teams ,EVALUATION ,DISEASE complications ,SYMPTOMS - Abstract
Guillain-Barre syndrome (GBS) is a debilitating condition characterized by acute or sub-acute autoimmune inflammation affecting the peripheral nervous system. One of its most common residual defects is bilateral foot drop, significantly impairing balance, and functional independence. This article investigates the efficacy of balance training in patients with bilateral foot drop post-GBS. The study, conducted on 18 patients, aimed to assess the impact of balance exercises, including Swiss ball and wobble board exercises, over three weeks. Baseline assessments were conducted using the Berg Balance Scale, Functional Independence Measure, and Hughes GBS Disability Scale. Results showed significant improvements in balance, functional independence, and disability scores post-intervention. GBS typically presents with pain, weakness, paresthesia, and decreased reflexes, leading to various functional limitations. Rehabilitation strategies must address these challenges early on, emphasizing posture, range of motion, and muscle strength to prevent contractures and improve function. Correcting foot drop is crucial for restoring functional capacity and independence. Balance is a key aspect of functional recovery in GBS patients, as it affects mobility and reduces the risk of falls. Balance training targets proprioception, muscle strength, and coordination, facilitating improvements in postural control and gait. The study's findings suggest that balance training effectively enhances outcomes for individuals with bilateral foot drop post-GBS. However, it is essential to consider the self-limiting nature of the disease and the potential for spontaneous improvement over time. Long-term follow-up studies are warranted to evaluate the sustained benefits of balance training and the natural course of recovery in GBS patients. The article underscores the multidisciplinary approach required for GBS rehabilitation, involving physiotherapy, neurology, and other healthcare professionals. By addressing the complex impairments associated with GBS, tailored rehabilitation programs can optimize functional outcomes and improve the quality of life for affected individuals. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
49. Zika Virus Neuropathogenesis—Research and Understanding.
- Author
-
Metzler, Anna D. and Tang, Hengli
- Subjects
SERTOLI cells ,CELL physiology ,PROGENITOR cells ,CELL cycle ,STEM cells - Abstract
Zika virus (ZIKV), a mosquito-borne flavivirus, is prominently associated with microcephaly in babies born to infected mothers as well as Guillain-Barré Syndrome in adults. Each cell type infected by ZIKV—neuronal cells (radial glial cells, neuronal progenitor cells, astrocytes, microglia cells, and glioblastoma stem cells) and non-neuronal cells (primary fibroblasts, epidermal keratinocytes, dendritic cells, monocytes, macrophages, and Sertoli cells)—displays its own characteristic changes to their cell physiology and has various impacts on disease. Here, we provide an in-depth review of the ZIKV life cycle and its cellular targets, and discuss the current knowledge of how infections cause neuropathologies, as well as what approaches researchers are currently taking to further advance such knowledge. A key aspect of ZIKV neuropathogenesis is virus-induced neuronal apoptosis via numerous mechanisms including cell cycle dysregulation, mitochondrial fragmentation, ER stress, and the unfolded protein response. These, in turn, result in the activation of p53-mediated intrinsic cell death pathways. A full spectrum of infection models including stem cells and co-cultures, transwells to simulate blood–tissue barriers, brain-region-specific organoids, and animal models have been developed for ZIKV research. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Clinical Characteristics and Prognosis of ICU-Admitted Patients with Guillain-Barre Syndrome: A Report from a Large Teaching Hospital in South Iran
- Author
-
Vida Naderi-boldaji, Farid Zand, Naeimehossadat Asmarian, Hoda Marbooti, Mansoor Masjedi, Seyedeh Maryam Tabibzadeh, Zahra Esmaeilinezhad, and Masoume Nazeri
- Subjects
guillain-barre syndrome ,apache ii ,immunoglobulins, intravenous ,Medicine (General) ,R5-920 - Abstract
Background: Guillain-Barre Syndrome (GBS) is the most prevalent acute peripheral polyneuropathy disorder. The disparities between populations and variations in the major risk factors highlight the importance of country-specific studies. This study aimed to report clinical characteristics and outcomes of ICU-admitted patients with GBS in an academic medical center in Iran. Methods: The data were collected retrospectively from all patients with GBS admitted to Namazi Hospital, affiliated with Shiraz University of Medical Sciences, (Shiraz, Iran), between March 2016 to March 2021. Specialized neurological information and the Acute Physiology and Chronic Health Evaluation (APACHE II) score were recorded. The SPSS software was used to analyze the data. The analyzed data were reported as numbers and percentages, or mean±SD, or median(Interquartile) Results: The study included 132 GBS patients, with an average age of 47.87±15.4 years and a male-to-female ratio of 1.69:1. More than half of the patients (58.5%) were classified as having an axonal disease. In patients with axonal illness, 51.4% of patients had lower limb powers
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.